콜라겐 상처 치료용 파우더 시장 규모, 점유율 및 동향 분석 보고서 : 원료별, 제품별, 용도별, 최종 용도별, 유통 채널별, 지역별 및 부문별 전망(2026-2033년)

Collagen Wound Powder Market Summary

The global collagen wound powder market size was valued at USD 107.5 million in 2025 and is projected to grow from USD 111.5 million in 2026 to USD 145.8 million by 2033, at a CAGR of 3.9% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 44.2% in 2025. The industry is driven by the rising prevalence of diabetic foot ulcers, pressure ulcers, and other chronic wounds.

Global Collagen Wound Powder Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global collagen wound powder market report based on source, product, application, end-use, distribution channel and region:

• Source Outlook (Revenue, USD Million, 2021 - 2033)
• Bovine-Derived
• Porcine-Derived
• Marine/Fish-Derived
• Recombinant / Human-Derived
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Pure / Native Collagen Powder
• Composite / Combination Collagen Powder
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Chronic Wounds
• Diabetic Foot Ulcers
• Pressure Injuries / Ulcers
• Venous Leg Ulcers
• Acute Wounds
• Partial-Thickness Burns (2nd Degree)
• Traumatic & Surgical Wounds
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Surgical Centers
• Specialty Wound Care Clinics
• Long-Term Care / Skilled Nursing Facilities
• Home care
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Direct Institutional Sales (GPOs / IDNs)
• Specialty Medical Distributors (DME Suppliers)
• Specialty / Online Medical Distributors
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Source
  • 1.1.2. Product Type
  • 1.1.3. Application
  • 1.1.4. End Use
  • 1.1.5. Distribution Channel
  • 1.1.6. Regional scope
  • 1.1.7. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. List of Secondary Sources
• 1.7. List of Primary Sources
• 1.8. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Collagen Wound Powder Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of chronic wounds
    • 3.2.1.2. Growing adoption of advanced wound care
    • 3.2.1.3. Advantages of powder formulation
    • 3.2.1.4. Increasing diabetic population
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High product cost
    • 3.2.2.2. Source-related concerns
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Expansion in emerging markets
    • 3.2.3.2. Development of novel collagen sources
    • 3.2.3.3. Integration with advanced wound technologies
    • 3.2.3.4. Growing home-based wound care
  • 3.2.4. Market challenge analysis
    • 3.2.4.1. Clinical evidence requirements
    • 3.2.4.2. Regulatory and quality requirements
• 3.3. Collagen Wound Powder Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. Collagen Wound Powder Market: Source Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Collagen Wound Powder Market Source Movement Analysis
• 4.3. Global Collagen Wound Powder Market Size & Trend Analysis, by Source, 2021 to 2033 (USD Million)
• 4.4. Bovine-Derived
  • 4.4.1. Bovine-derived market estimates and forecasts for 2021 to 2033, (USD Million)
• 4.5. Porcine-Derived
  • 4.5.1. Porcine-derived market estimates and forecasts for 2021 to 2033, (USD Million)
• 4.6. Marine/Fish-Derived
  • 4.6.1. Marine/fish-derived market estimates and forecasts for 2021 to 2033, (USD Million)
• 4.7. Recombinant / Human-Derived
  • 4.7.1. Recombinant / human-derived market estimates and forecasts for 2021 to 2033, (USD Million)

Chapter 5. Collagen Wound Powder Market: Product Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Collagen Wound Powder Market Product Movement Analysis
• 5.3. Global Collagen Wound Powder Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 5.4. Pure / Native Collagen Powder
  • 5.4.1. Pure / native collagen powder market estimates and forecasts for 2021 to 2033, (USD Million)
• 5.5. Composite / Combination Collagen Powder
  • 5.5.1. Composite / combination collagen powder market estimates and forecasts for 2021 to 2033, (USD Million)

Chapter 6. Collagen Wound Powder Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Collagen Wound Powder Market Application Movement Analysis
• 6.3. Global Collagen Wound Powder Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. Chronic Wounds
  • 6.4.1. Chronic wounds market estimates and forecasts for 2021 to 2033, (USD Million)
  • 6.4.2. Diabetic foot ulcers
    • 6.4.2.1. Diabetic foot ulcers market estimates and forecasts for 2021 to 2033, (USD Million)
  • 6.4.3. Pressure injuries / ulcers
    • 6.4.3.1. Pressure injuries / ulcers market estimates and forecasts for 2021 to 2033, (USD Million)
  • 6.4.4. Venous Leg Ulcers
    • 6.4.4.1. Venous leg ulcers market estimates and forecasts for 2021 to 2033, (USD Million)
• 6.5. Acute Wounds
  • 6.5.1. Acute wounds market estimates and forecasts for 2021 to 2033, (USD Million)
  • 6.5.2. Partial-thickness burns (2nd degree)
    • 6.5.2.1. Partial-thickness burns (2nd degree) market estimates and forecasts for 2021 to 2033, (USD Million)
  • 6.5.3. Traumatic & surgical wounds
    • 6.5.3.1. Traumatic & surgical wounds market estimates and forecasts for 2021 to 2033, (USD Million)

Chapter 7. Collagen Wound Powder Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Collagen Wound Powder Market End Use Movement Analysis
• 7.3. Global Collagen Wound Powder Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 7.4. Hospitals & Surgical Centers
  • 7.4.1. Hospitals & surgical centers market estimates and forecasts for 2021 to 2033, (USD Million)
• 7.5. Specialty Wound Care Clinics
  • 7.5.1. Specialty wound care clinics market estimates and forecasts for 2021 to 2033, (USD Million)
• 7.6. Long-Term Care / Skilled Nursing Facilities
  • 7.6.1. Long-term care / skilled nursing facilities market estimates and forecasts for 2021 to 2033, (USD Million)
• 7.7. Home care
  • 7.7.1. Home care market estimates and forecasts for 2021 to 2033, (USD Million)

Chapter 8. Collagen Wound Powder Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Collagen Wound Powder Market Distribution Channel Movement Analysis
• 8.3. Global Collagen Wound Powder Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 8.4. Direct Institutional Sales (GPOs / IDNs)
  • 8.4.1. Direct institutional sales (GPOs / IDNs) market estimates and forecasts for 2021 to 2033, (USD Million)
• 8.5. Specialty Medical Distributors (DME Suppliers)
  • 8.5.1. Specialty medical distributors (DME suppliers) market estimates and forecasts for 2021 to 2033, (USD Million)
• 8.6. Specialty / Online Medical Distributors
  • 8.6.1. Specialty / online medical distributors market estimates and forecasts for 2021 to 2033, (USD Million)

Chapter 9. Collagen Wound Powder Market: Regional Estimates & Trend Analysis by Source, Application, Product, End Use and Distribution Channel

• 9.1. Regional Dashboard
• 9.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 9.3. North America
  • 9.3.1. Market estimates and forecast, 2021 - 2033 (Revenue, USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Competitive scenario
    • 9.3.2.3. Regulatory framework
    • 9.3.2.4. Reimbursement scenario
    • 9.3.2.5. U.S. market estimates and forecasts, 2021 - 2033
  • 9.3.3. Canada
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Competitive scenario
    • 9.3.3.3. Regulatory framework
    • 9.3.3.4. Reimbursement scenario
    • 9.3.3.5. Canada market estimates and forecasts, 2021 - 2033
  • 9.3.4. Mexico
    • 9.3.4.1. Key country dynamics
    • 9.3.4.2. Competitive scenario
    • 9.3.4.3. Regulatory framework
    • 9.3.4.4. Reimbursement scenario
    • 9.3.4.5. Mexico market estimates and forecasts, 2021 - 2033
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Competitive scenario
    • 9.4.1.3. Regulatory framework
    • 9.4.1.4. Reimbursement scenario
    • 9.4.1.5. UK market estimates and forecasts, 2021 - 2033
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Competitive scenario
    • 9.4.2.3. Regulatory framework
    • 9.4.2.4. Reimbursement scenario
    • 9.4.2.5. Germany market estimates and forecasts, 2021 - 2033
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Competitive scenario
    • 9.4.3.3. Regulatory framework
    • 9.4.3.4. Reimbursement scenario
    • 9.4.3.5. France market estimates and forecasts, 2021 - 2033
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Competitive scenario
    • 9.4.4.3. Regulatory framework
    • 9.4.4.4. Reimbursement scenario
    • 9.4.4.5. Italy market estimates and forecasts, 2021 - 2033
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Competitive scenario
    • 9.4.5.3. Regulatory framework
    • 9.4.5.4. Reimbursement scenario
    • 9.4.5.5. Spain market estimates and forecasts, 2021 - 2033
  • 9.4.6. Denmark
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Competitive scenario
    • 9.4.6.3. Regulatory framework
    • 9.4.6.4. Reimbursement scenario
    • 9.4.6.5. Denmark market estimates and forecasts, 2021 - 2033
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Competitive scenario
    • 9.4.7.3. Regulatory framework
    • 9.4.7.4. Reimbursement scenario
    • 9.4.7.5. Sweden market estimates and forecasts, 2021 - 2033
  • 9.4.8. Norway
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Competitive scenario
    • 9.4.8.3. Regulatory framework
    • 9.4.8.4. Reimbursement scenario
    • 9.4.8.5. Norway market estimates and forecasts, 2021 - 2033
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Competitive scenario
    • 9.5.1.3. Regulatory framework
    • 9.5.1.4. Reimbursement scenario
    • 9.5.1.5. Japan market estimates and forecasts, 2021 - 2033
  • 9.5.2. India
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Competitive scenario
    • 9.5.2.3. Regulatory framework
    • 9.5.2.4. Reimbursement scenario
    • 9.5.2.5. India market estimates and forecasts, 2021 - 2033
  • 9.5.3. China
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Competitive scenario
    • 9.5.3.3. Regulatory framework
    • 9.5.3.4. Reimbursement scenario
    • 9.5.3.5. China market estimates and forecasts, 2021 - 2033
  • 9.5.4. South Korea
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Competitive scenario
    • 9.5.4.3. Regulatory framework
    • 9.5.4.4. Reimbursement scenario
    • 9.5.4.5. South Korea market estimates and forecasts, 2021 - 2033
  • 9.5.5. Australia
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Competitive scenario
    • 9.5.5.3. Regulatory framework
    • 9.5.5.4. Reimbursement scenario
    • 9.5.5.5. Australia market estimates and forecasts, 2021 - 2033
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Competitive scenario
    • 9.5.6.3. Regulatory framework
    • 9.5.6.4. Reimbursement scenario
    • 9.5.6.5. Thailand market estimates and forecasts, 2021 - 2033
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Competitive scenario
    • 9.6.1.3. Regulatory framework
    • 9.6.1.4. Reimbursement scenario
    • 9.6.1.5. Brazil market estimates and forecasts, 2021 - 2033
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Competitive scenario
    • 9.6.2.3. Regulatory framework
    • 9.6.2.4. Reimbursement scenario
    • 9.6.2.5. Argentina market estimates and forecasts, 2021 - 2033
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Competitive scenario
    • 9.7.1.3. Regulatory framework
    • 9.7.1.4. Reimbursement scenario
    • 9.7.1.5. South Africa market estimates and forecasts, 2021 - 2033
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Competitive scenario
    • 9.7.2.3. Regulatory framework
    • 9.7.2.4. Reimbursement scenario
    • 9.7.2.5. Saudi Arabia market estimates and forecasts, 2021 - 2033
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Competitive scenario
    • 9.7.3.3. Regulatory framework
    • 9.7.3.4. Reimbursement scenario
    • 9.7.3.5. UAE market estimates and forecasts, 2021 - 2033
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Competitive scenario
    • 9.7.4.3. Regulatory framework
    • 9.7.4.4. Reimbursement scenario
    • 9.7.4.5. Kuwait market estimates and forecasts, 2021 - 2033

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
  • 10.2.1. Innovators
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Human BioSciences
    • 10.3.3.1. Company overview
    • 10.3.3.2. Financial performance
    • 10.3.3.3. Product benchmarking
    • 10.3.3.4. Strategic initiatives
  • 10.3.4. Ventris Medical, LLC
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Product benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Roosin Medical Co.,Ltd
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Product benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Foryou Medical
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Product benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. EUCARE PHARMACEUTICALS (P) LTD. (International Urgo Medical)
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Product benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Synerheal Pharmaceuticals
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Product benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. ColoGenesis Healthcare Pvt.
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Product benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Lotus Surgicals Pvt. Ltd. (Ti Medical Pvt. Ltd.)
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Product benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. Ovigenex, LLC
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Product benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Maiden Biosciences, Inc.
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Product benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. MPM Medical
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Product benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Sanara MedTech Inc. (MIMEDX Group, Inc.)
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Product benchmarking
    • 10.3.14.4. Strategic initiatives
  • 10.3.15. Royal Biologics Inc.
    • 10.3.15.1. Company overview
    • 10.3.15.2. Financial performance
    • 10.3.15.3. Product benchmarking
    • 10.3.15.4. Strategic initiatives
  • 10.3.16. DermaRite Industries, LLC (SionBrands)
    • 10.3.16.1. Company overview
    • 10.3.16.2. Financial performance
    • 10.3.16.3. Product benchmarking
    • 10.3.16.4. Strategic initiatives
  • 10.3.17. HARTMANN USA, INC.
    • 10.3.17.1. Company overview
    • 10.3.17.2. Financial performance
    • 10.3.17.3. Product benchmarking
    • 10.3.17.4. Strategic initiatives
  • 10.3.18. MEDLINE
    • 10.3.18.1. Company overview
    • 10.3.18.2. Financial performance
    • 10.3.18.3. Product benchmarking
    • 10.3.18.4. Strategic initiatives
  • 10.3.19. L&R USA INC.
    • 10.3.19.1. Company overview
    • 10.3.19.2. Financial performance
    • 10.3.19.3. Product benchmarking
    • 10.3.19.4. Strategic initiatives
• 10.4. Estimated Company Market Share Analysis, 2025
• 10.5. List of Other Key Market Players